Last Updated: June 24, 2026

Drugs Containing Excipient (Inactive Ingredient) D&C RED NO. 27 ALUMINUM LAKE


✉ Email this page to a colleague

« Back to Dashboard


Market Dynamics and Financial Trajectory for D&C Red No. 27 Aluminum Lake

Last updated: April 24, 2026

D&C Red No. 27 Aluminum Lake is a coal-tar-derived colorant sold as an “aluminum lake” pigment for regulated applications where tinting strength, batch-to-batch color control, and compatibility with polymeric or semi-solid matrices matter. The market dynamics follow pigment fundamentals (input costs, certification and regulatory continuity, and batch manufacturing yields), plus excipient-specific demand drivers tied to coatings, tablets/capsules, and topical/dermal formulations that remain within colorant-permitted pathways.

This analysis frames the financial trajectory through: (i) demand channels, (ii) supply and cost drivers for aluminum-lake pigments, (iii) regulatory continuity and reformulation risk, and (iv) pricing power under supplier concentration typical of specialty colorants.


Where does demand come from and how is it trending?

Primary end-use channels

D&C Red No. 27 Aluminum Lake is used to deliver red color with improved dispersion stability versus soluble dyes. Demand typically concentrates in regulated dosage forms and finished goods where color must be stable through manufacturing and storage.

Key application clusters:

  • Oral solid dosage colorants (tablets and capsules): the lake form supports better pigment dispersion and often improved color retention through compression and coating steps.
  • Topical and transdermal formulations (where permitted): lakes are used when formulators need colorants that behave differently than fully soluble dyes.

Commercial demand pattern

Colorant consumption in pharma tracks formulation cycles, approvals, and product line continuity more than it tracks patient volume. In practical terms, sales rise and fall with:

  • New product launches that specify D&C Red No. 27 in a finished drug or approved excipient blend.
  • Lifecycle reforms (reformulation, line relocations, or packaging/processing changes) that can replace one lake pigment with another.
  • Batch-size economics in pigment manufacturing: once a supplier qualifies, downstream buyers tend to lock in for color consistency until a documented change is feasible.

Market maturity

Aluminum lake pigments are mature specialty chemicals. Expect demand to be steadier than for novel drug substances but more exposed to commodity input swings and compliance-driven supplier qualification cycles.


What supply-side forces control availability and pricing?

Input and process economics

Aluminum lakes require:

  • A colorant precursor (synthetic organic pigment intermediate chain associated with FD&C/D&C dye lines).
  • Aluminum salt precipitation and filtration steps that determine yield, particle characteristics, and dispersion performance.

Pricing pressure typically comes from:

  • Precursor feedstock costs (coal-tar-derived chemical economics).
  • Aluminum and process utilities tied to precipitation and post-processing.
  • Waste and solvent handling in pigment purification steps.

Supplier concentration and qualification friction

Specialty pharmaceutical colorants usually have fewer qualified suppliers than bulk industrial pigments. That drives:

  • Narrower substitution during shortages.
  • Longer buyer qualification windows when changes are proposed.
  • More stable long-term pricing once qualified, with short bursts of volatility during regulatory or capacity disruptions.

How do regulations and regulatory continuity affect the financial trajectory?

Regulatory identity

D&C Red No. 27 is an identified colorant permitted for specified uses in the U.S. framework for color additives. The aluminum-lake form is a recognized physical form used to meet performance requirements.

Regulatory anchor:

  • 21 CFR provisions for certified color additives underpin the U.S. market structure, including certification and listing status for each color additive identity and its permitted use. (See U.S. FDA color additive certification framework and D&C color additive regulations.) [1][2]

Compliance-driven switching risk

Financially, the biggest formulation risk is not “replacement demand.” It is qualification risk. If buyers must switch due to supply constraints or performance issues, they pay:

  • Technical comparability costs (color strength, dispersibility, stability).
  • Batch verification costs.
  • Submission or documentation work tied to finished-product change management.

That friction tends to:

  • Support repeat volume once a supplier is locked.
  • Create pricing resilience during constrained supply.

What is the pricing power model for D&C Red No. 27 aluminum lake?

Price behavior

For mature excipient pigments, pricing power is driven by three levers:

  1. Certification and supply continuity

    • If certification status is intact and production is stable, buyers restock.
    • During capacity reductions or regulatory interruptions, price rises track supply scarcity, not demand spikes.
  2. Functional performance

    • Buyers pay for consistent tint, particle characteristics, and dispersion behavior that reduce downstream rework.
  3. Substitution friction

    • Even if alternate red lake pigments exist, buyers face comparability and approval pathway costs for finished products.

Margin dynamics

Typical financial structure for this category:

  • Gross margin is sensitive to input feedstock and yields (precipitation yield, filtration and drying efficiency).
  • Operating margin is sensitive to compliance costs (quality systems, testing, certification logistics).

Because the material is a specialty excipient, margins can remain positive even when commodity inputs soften, but the direction of earnings tends to follow:

  • Precursor cost trend plus utilization rate (factory throughput).
  • Certification and batch rejection rates.

How do volume and product mix shift over time?

Mix drivers

  • Downstream specification strictness increases with customer type (large CDMOs and branded pharma) and with higher-performance formulation needs (better dispersion, lower migration).
  • Geography matters because compliance timelines and purchasing cycles differ across markets.

Volume drivers

  • New formulation introductions are slower-moving than general excipient consumption.
  • Line extensions (additional strengths or dosage forms of existing drugs) can add steady incremental volume if the color specification stays constant.

Scenario-based financial trajectory (directional)

Below is a directional framework for how earnings and cash flow typically move for a specialty pharma colorant lake over a 2- to 5-year horizon.

Base-case trajectory

  • Revenue: modest growth or flat-to-low single digits, supported by restocking and product line continuity.
  • Gross margin: stable to slightly down if aluminum and precursor costs rise or if utilization falls.
  • Operating margin: stable, driven by fixed compliance overhead and batch production stability.

Bull case trajectory (tight supply or rising input costs)

  • Revenue: higher due to price recovery and constrained availability.
  • Gross margin: improves if producers can pass through input cost increases faster than rivals.
  • Cash flow: can tighten if inventory builds during volatility, then releases when supply normalizes.

Bear case trajectory (substitution and normalization)

  • Revenue: compressed if customers reformulate to alternative colorants or simplify specs.
  • Gross margin: down if input costs fall but pricing does not reset quickly, or if yields degrade.
  • Operating margin: pressured by quality and certification costs during periods of process instability.

What KPIs map best to the financial outlook?

For D&C Red No. 27 aluminum lake, the KPIs that track financial performance best are:

KPI What it signals Financial impact channel
Certification continuity Ongoing ability to supply certified material Pricing resilience and supply certainty
Batch rejection rate / OOS frequency Process stability and compliance Direct gross margin hit
Dispersion performance consistency Customer retention and spec compliance Volume retention and reduced re-qualification risk
Factory utilization Production throughput vs fixed compliance overhead Operating margin and working capital
Input index for colorant precursors Cost pressure in pigment formation Gross margin direction

Key competitor and substitution dynamics

Substitution occurs at the finished-product level, not at the excipient level in most pharma contexts. That means competition is shaped by:

  • Qualification status with major formulators and CDMOs.
  • Availability of certified material at consistent quality.
  • Color performance and compatibility with matrix polymers (coatings, films, and semi-solid bases).

Competitors can pressure share if they offer:

  • Comparable tint strength with better dispersion.
  • Lower defect rates.
  • Better lead times.

What does due diligence for financial trajectory look like?

Investors and R&D sponsors typically validate financial durability using:

  • Supply track record (on-time certification shipments).
  • Batch quality statistics (OOS and rework patterns).
  • Customer retention (repeat orders from dosage form manufacturers).
  • Raw material sourcing stability (precursor and aluminum-related cost exposure).

These items govern whether price and margin stay intact under volatility.


Key Takeaways

  • D&C Red No. 27 Aluminum Lake behaves like a mature specialty pigment: revenue tracks formulation continuity and restocking cycles, while margins depend on batch yields, certification continuity, and input-cost pass-through.
  • Pricing power is strongest when supply is constrained and when substitution is costly due to qualification and comparability friction.
  • Regulatory continuity under the certified color additive framework supports supply stability, but quality performance (OOS and rejection rates) is a direct driver of gross margin.
  • The financial trajectory over a 2- to 5-year horizon is typically stable-to-moderate growth in base cases, with margin volatility driven by precursor and aluminum-linked process economics.

FAQs

1) Is D&C Red No. 27 Aluminum Lake demand tied to patient growth?

No. It is driven primarily by product formulation specifications and manufacturing restocking cycles for dosage forms and topical applications where the colorant remains in approved compositions.

2) What most affects gross margin for aluminum lake pigments?

Batch yield, filtration and drying efficiency, and defect/OOS rates. Input precursor and aluminum-linked processing costs determine the direction of margin changes.

3) Why can pricing stay firm even without major demand growth?

Specialty colorants face supplier qualification friction and certification constraints. Once customers lock a supplier for color consistency, substitution is costly.

4) What regulatory factors influence supply risk?

The U.S. certified color additive framework requires that eligible color additives maintain certification status for permitted uses, affecting continuity and logistics. [1][2]

5) What signals an early shift toward lower volumes or margins?

Rising customer re-qualification events, increased OOS/defect rates, longer lead times, and documented finished-product reformulation away from the specified colorant identity.


References

[1] U.S. Food and Drug Administration. (n.d.). Color additives: Certified color additives. https://www.fda.gov/food/color-additives-petitions/color-additives-certified-color-additives
[2] U.S. Food and Drug Administration. (n.d.). Color additives (general). 21 CFR Parts 70-80. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-70

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.